SARS-CoV-2 Does Not Spread Through Extracorporeal Membrane Oxygenation or Dialysis Membranes

To the Editor:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a major worldwide health threat in just a few weeks (1). ICU admission and the recourse to extracorporeal organ support, such as continuous renal replacement therapy (CRRT) or venovenous extracorporeal membrane oxygenation (VV-ECMO) may be needed in the most severe forms of the disease (2). Because SARS-CoV-2 viremia has been reported in some cases (3), it has been hypothesized that this small virus (average size of 125 nm) (4) could pass through polymethylpentene ECMO membranes or acrylonitrile/sodium methallylsulfonate CRRT membranes. In this study, we investigated whether SARS-CoV-2 RNA was detected in the dialysis effluent fluid or in the condensate collected from the ECMO membrane exhalation port (gas outlet) when the virus was present in the lower respiratory tract and the plasma.

Methods

We evaluated consecutive patients admitted to three university ICUs in Paris who had severe SARS-CoV-2 infection and required CRRT (hemodiafiltration or hemofiltration), VV-ECMO, or both. Samples were obtained from respiratory tract, plasma, the dialysis effluent fluid, and from 5 to 10 ml of condensate collected from the ECMO membrane gas outlet within 48 hours after ECMO initiation. Real-time RT-PCR targeting the E (envelope) gene of SARS-CoV-2 was performed as previously described (5). The cycle threshold (CT) values of RT-PCR were used as indicators of the RNA viral load in samples: the lower the CT, the higher the RNA viral load. The estimated probability (95% confidence interval [CI]) and the binomial probability of SARS-CoV-2 in the gas outlet and the dialysis fluid were reported, respectively. Ethical approval was applied to our local ethics committee (CER Sorbonne University, N°2020–CER-2020–32).

Results

All 27 patients were on mechanical ventilation, and 25/27 were supported by VV-ECMO (20 patients with Quadrox oxygenator [Getinge] and 5 patients with Oxymedos oxygenator [Xenios]). In addition, 8/27 patients received CRRT (Prismaflex, Baxter). CRRT was administered using

hemofiltration in four patients and hemodiafiltration in four patients. Main findings are presented in Figure 1. SARS-CoV-2 RNA was detected in all samples from patients' lower respiratory tract (median CT, 28; 25–75% interquartile range, 22–31) and in the plasma of 13/27 of them (median CT, 29; interquartile range, 29–30). However, SARS-CoV-2 RNA was not detected in the membrane oxygenator gas outlet condensate, whether plasma RNA was positive ($n = 13/25$) or negative ($n = 12/25$). Similarly, SARS-CoV-2 RNA was not present in the dialysis effluent of the eight patients on CRRT whether plasma PCR was positive ($n = 4/8$) or negative ($n = 4/8$). Therefore, the estimated probability of a positive SARS-CoV-2 RNA in the membrane oxygenator gas outlet condensate and in the dialysis fluid were 0.0 (95% CI, 0.00–0.14) and 0.0 (95% CI, 0.00–0.37), respectively. On the basis of binomial probabilities of our results, the prevalence of a positive SARS-CoV-2 RNA in the ECMO gas outlet and in the dialysis fluid will likely be lower than 11% and 31%, respectively. Individual data for SARS-CoV-2 RNA detection in lower respiratory tracts, plasma, dialysis fluid, and ECMO membrane are given in Table 1 with the CT values resulting from PCR for lower respiratory tracts (column 2) and plasma (column 3).

Discussion

To the best of our knowledge, this is the first study that investigated the risks for SARS-CoV-2 dissemination through membranes used for extra corporeal organ support in critically ill patients. Though a recent report revealed that SARS-CoV-2 is almost always present in the lower respiratory tract, sometimes in the feces but never in urine samples (3), our findings are reassuring regarding the risk of contamination for ICU professionals when treating patients on VV-ECMO or CRRT. Specifically, our findings do not support the routine use of a viral filter on the exhaust of the commonly used polymethylpentene-based ECMO membrane lungs. Prevention and education of healthcare workers should therefore remain focused on limiting the risks of virus spreading during invasive respiratory procedures, such as high-flow oxygenation, mouth care, intubation, or microbiological sampling of nasopharyngeal, tracheal, or bronchioalveolar secretions. The number of patients with CRRT ($n = 8$) is limited, but the fact that SARS-CoV-2 PCR was negative in all dialysis effluent is somehow reassuring. Lastly, we cannot rule out that longer ECMO runs could progressively lead to membrane alteration, plasma leakage, and ultimately SARS-CoV-2 aerosolization. However, we purposely chose to investigate the risk of virus spreading within 48 hours after ECMO and CRRT initiation as the viral load—if present in the plasma—is expected to progressively decline afterward. Though our findings may not alter practices, they may contribute to address legitimate interrogations raised by caregivers and reinforce adhesion and trust into infection control measure policies, which is likely to play a major role against the outbreak spreading. ∎

Figure 1. Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in dialysis effluent fluid or in the exhalation port of the extracorporeal membrane oxygenation membrane according to plasma detection of the viral RNA. CRRT = continuous renal replacement therapy; ECMO = extracorporeal membrane oxygenation.

Table 1. Detection of SARS-CoV-2 RNA in the Condensate Collected from the ECMO Membrane Gas Outlet and in the Dialysis Effluent Fluid

	Lower Respiratory Tracts RT-PCR (CT)	Plasma RT-PCR (CT)	Dialysis RT-PCR (CT)	ECMO Membrane Gas Outlet RT-PCR (CT)
Patient 1	32	Undetectable	No CRRT	Undetectable
Patient 2	13	29	Undetectable	Undetectable
Patient 3	Positive*	33	Undetectable	Undetectable
Patient 4	28	Undetectable	Undetectable	No ECMO
Patient 5	Positive*	Undetectable	Undetectable	No ECMO
Patient 6	29	30	No CRRT	Undetectable
Patient 7	35	Undetectable	No CRRT	Undetectable
Patient 8	21	Undetectable	No CRRT	Undetectable
Patient 9	24	28	No CRRT	Undetectable
Patient 10	24	Undetectable	Undetectable	Undetectable
Patient 11	19	30	Undetectable	Undetectable
Patient 12	26	30	Undetectable	Undetectable
Patient 13	29	Undetectable	No CRRT	Undetectable
Patient 14	36	Undetectable	No CRRT	Undetectable
Patient 15	33	Undetectable	No CRRT	Undetectable
Patient 16	Positive*	50	No CRRT	Undetectable
Patient 17	Positive*	Undetectable	No CRRT	Undetectable
Patient 18	18	29	No CRRT	Undetectable
Patient 19	18	30	No CRRT	Undetectable
Patient 20	27	Undetectable	No CRRT	Undetectable
Patient 21	15	28	No CRRT	Undetectable
Patient 22	30	Undetectable	No CRRT	Undetectable
Patient 23	30	29	Undetectable	Undetectable
Patient 24	29	Undetectable	No CRRT	Undetectable
Patient 25	23	29	No CRRT	Undetectable
Patient 26	33	Undetectable	No CRRT	Undetectable
Patient 27	32	28	No CRRT	Undetectable

Definition of abbreviations: CRRT = continuous renal replacement therapy; CT = cycle threshold; ECMO = extracorporeal membrane oxygenation; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
*Patient tested positive before being transferred in our center; no CT was provided.

Martin Dres, M.D., Ph.D.*
UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique
Paris, France
and
AP-HP Sorbonne Université
Paris, France

Sonia Burrel, M.D., Ph.D.
David Boutolleau, M.D., Ph.D.
INSERM UMR_S 1136
Paris, France
and
AP-HP Sorbonne Université
Paris, France

Guillaume Voiriot, M.D., Ph.D.
AP-HP Sorbonne Université
Paris, France

Alexandre Demoule, M.D., Ph.D.
UMR_S 1158 Neurophysiologie respiratoire expérimentale et clinique
Paris, France
and
AP-HP Sorbonne Université
Paris, France

Alain Combes, M.D., Ph.D.
Guillaume Lebreton, M.D., Ph.D.
Matthieu Schmidt, M.D., Ph.D.
UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition
Paris, France
and
AP-HP Sorbonne Université
Paris, France

For the Groupe de Recherche Clinique RESPIRE

*Corresponding author (e-mail: martin.dres@aphp.fr).

References

1. MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. *JAMA* [online ahead of print] 19 Feb 2020; DOI: 10.1001/jama.2020.2342.

2. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. *Lancet Respir Med* 2020;8:518–526.

3. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA* 2020;323:1843–1844.

4. Fisher D, Heymann D. Q&A: the novel coronavirus outbreak causing COVID-19. *BMC Med* 2020;18:57.

5. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 2020;25:2000045.

ⓘ Check for updates

Extracorporeal Membrane Oxygenation for Critically Ill Patients with COVID-19–related Acute Respiratory Distress Syndrome: Worth the Effort?

To the Editor:

According to Chinese and Italian reports, 15–42% of patients with coronavirus disease (COVID-19) develop acute respiratory distress syndrome (ARDS), with a 60% mortality rate (1–3). Venovenous extracorporeal membrane oxygenation (VV-ECMO) is therefore considered a rescue therapy to be used in the most severe ARDS, as recommended by the World Health Organization's interim guidelines for the management of patients with COVID-19 (4). However, without a significant impact on mortality, the benefit of ECMO in ARDS remains controversial (5). Generally, only few data on the use of ECMO in the present pandemic are available (1, 2) with a short follow-up (6, 7). However, accurately selecting patients with COVID-19–related ARDS, who may be good candidates for ECMO support, is important during a pandemic characterized by limited medical resources.

Methods

We prospectively included all patients referred to the five ICUs of the Strasbourg University Hospital, between March 3 and April 1, 2020, for severe ARDS due to COVID-19 (confirmed by RT-PCR test), and that had been supported by ECMO after failure of optimal medical treatment, including neuromuscular blocking agents, protective ventilation, and high positive end-expiratory pressure (PEEP). According to EOLIA (ECMO to Rescue Lung Injury in Severe ARDS) criteria (5), patients were eligible for ECMO if they developed a refractory ARDS defined by a $Pa_{O_2}/F_{I_{O_2}} < 80$ mm Hg or a pH < 7.25 with a $Pa_{CO_2} > 60$ mm Hg for more than 6 hours with a $F_{I_{O_2}} > 80\%$, despite low-pressure ventilation strategies and no participation of fluid overload. The contraindications for ECMO implantation were an age older than 70 years and severe comorbidities, including severe chronic respiratory failure, severe cardiac failure, and Child Pugh C cirrhosis. Invasive